A New Jersey neuroscientist deeply involved in Alzheimer’s research said that, in just two years, doctors may have the medicine to treat the brain-killing disease.

Family members and close friends are more sensitive to early signs of Alzheimer’s dementia than traditional screening tests, according to researchers at Washington University School of Medicine in St. Louis.

Memory lapses that occur with normal aging are a source of worry for many who fear Alzheimer’s disease. Now a new Mayo Clinic-led study published in the July 16 issue of the New England Journal of Medicine suggests that the carriers of a common genetic risk factor for Alzheimer’s disease begin to have memory declines in their mid-50s, far earlier than previously thought.

The first trial of a new model for testing Alzheimer’s treatments has reassured researchers that a promising class of drugs does not exacerbate the disease if treatment is interrupted.

Washington, May 26 : High levels of a protein, called GGA3, could prevent the accumulation of an enzyme linked to Alzheimer’s, found researchers at Tufts University School of Medicine.

Researchers at Tufts University School of Medicine have zeroed in on a protein that may play a role in the progression of Alzheimer’s disease. The team found that increasing levels of the protein (called GGA3) prevented the accumulation of an enzyme linked to Alzheimer’s. The strategy may lead to new treatments for the neurodegenerative disease.

Researchers at Tufts University School of Medicine have zeroed in on a protein that may play a role in the progression of Alzheimer’s disease. The team found that increasing levels of the protein (called GGA3) prevented the accumulation of an enzyme linked to Alzheimer’s. The strategy may lead to new treatments for the neurodegenerative disease.

Researchers at Tufts University School of Medicine have zeroed in on a protein that may play a role in the progression of Alzheimer’s disease.

Researchers from Boston University School of Medicine (BUSM) have shown that patients with Alzheimer’s disease (AD) are better able to remember new verbal information when it is provided in the context of music even when compared to healthy, older adults.

April 29, 2010 - Using a new mouse model of Alzheimer’s disease, researchers at Mount Sinai School of Medicine report to have found that Alzheimer’s pathology originates in Amyloid-Beta (Abeta) oligomers in the brain, rather than the amyloid plaques previously thought by many researchers to cause the disease.

April 28, 2010 - Older adults with evidence of amyloid in the brain but no clinical symptoms of Alzheimers disease have structures in the brain that dont communicate readily with each other, according to researchers at Washington University School of Medicine in St. Louis.

Drug maker Pfizer Inc. received the Connecticut bioscience community’s premier life science award for its Groton research into treatments for Alzheimer’s.

Using a new mouse model of Alzheimer’s disease, researchers at Mount Sinai School of Medicine have found that Alzheimer’s pathology originates in Amyloid-Beta (Abeta) oligomers in the brain, rather than the amyloid plaques previously thought by many researchers to cause the disease.

( The Mount Sinai Hospital / Mount Sinai School of Medicine ) Using a new mouse model of Alzheimer’s disease, researchers at Mount Sinai School of Medicine have found that Alzheimer’s pathology originates in Amyloid-Beta (Abeta) oligomers in the brain, rather than the amyloid plaques previously thought by many researchers to cause the disease.

The University of Pennsylvania and AstraZeneca announced a new collaborative research agreement to make use of their respective talents and resources in an effort to bridge the transition from drug discovery to development. Initially, the collaboration between Penn Medicine and AstraZeneca scientists will focus on generating new Alzheimer’s disease (AD) drug candidates for the clinical …

CHARITIES in Furness and South Lakeland have scooped more than £150,000 to help care for people with Alzheimer’s.

A “buddy program” at the Feinberg School of Medicine at Northwestern unites researchers and people with Alzheimer’s disease.

Researchers from Baylor College of Medicine in Houston, Texas studied 597 patients with Alzheimer’s disease in order to evaluate the reliability of the Alzheimer’s progression rate measure in predicting loss of cognition and function.

James Huysman, Ph.D., of Miami, co-author of a new book for caregivers, speaks on ‘Take Your Oxygen First! Compassion Fatigue and You’ at an educational conference presented March 3 at the Crowne Plaza hotel by Alzheimer’s Services of the Capital Area.

Researchers at NYU School of Medicine have found that elevated cerebrospinal fluid levels of phosphorylated tau231 (P-tau231), a damaged tau protein found in patients with Alzheimer’s disease, may be an early diagnostic biomarker for Alzheimer’s disease in healthy adults.The study published this month online by Neurobiology of Aging shows that high levels of P- tau231 predict future memory …